fls.txt
The Company evaluates the realizability of its deferred tax assets by tax-paying component and assesses the need for a valuation allowance on an annual and quarterly basis.


item1.txt
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The unaudited consolidated financial statements of Brooks Automation, Inc. and its subsidiaries (“Brooks”, or the “Company”) included herein have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP").
In the fourth quarter of fiscal year 2018, the Company entered into a definitive agreement to sell its semiconductor cryogenics business to Edwards Vacuum LLC (a member of the Atlas Copco Group), (the “Disposition”).
The Company determined that the cryogenics business met the “held for sale” criteria and the “discontinued operations” criteria in accordance with Financial Accounting Standard Boards (“FASB”) Accounting Standards Codification (“ASC”) 205, Presentation of Financial Statements, (“FASB ASC 205”) as of September 30, 2018.
The accompanying Consolidated Balance Sheet as of September 30, 2018 was derived from the audited annual consolidated financial statements as of the period then ended.
During the three months ended March 31, 2019, the Company identified a misclassification related to the presentation of the product and service revenue and the cost of product and service revenue related to GENEWIZ in the Company's Consolidated Statements of Operations for the three months ended December 31, 2018.
The Company concluded this misclassification was not material individually or in the aggregate to the financial statements presented for the three months ended December 31, 2018, and therefore, amendments of the previously filed Form 10-Q for the three months ended December 31, 2018 was not required.
Net foreign currency transaction and remeasurement losses totaled $0.6 million and $0.5 million, respectively, during the three months ended March 31, 2019 and 2018 and $0.6 million and $2.5 million, respectively, during the six months ended March 31, 2019 and 2018.
The targeted changes to the lessor accounting are not applicable to the Company because we are not in the industry to be targeted by the guidance.
The ASU clarifies that companies are exempt from making the interim period transition disclosures required by ASC 250, Accounting Changes and Error Corrections, for the period in which a change in accounting principle is made as a result of adopting ASC 842.
The Company is currently evaluating the impact of this ASU.
The amendment removes disclosure requirement for accumulated other comprehensive income expected to be recognized over the next year, information about plan assets to be returned to the entity, and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits.
The Company is currently evaluating the impact of this ASU.
Entities are required to estimate expected credit losses over the life of financial assets and record an allowance against the assets’ amortized cost basis to present them at the amount expected to be collected.


item2.txt
This section provides an analysis of our financial results for the three and six months ended March 31, 2019 compared to the three and six months ended March 31, 2018.
This Quarterly Report on Form 10‑Q contains statements that are, or may be considered to be, forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Gross margin was 40.6% for the three months ended March 31, 2019 as compared to 39.7% for the corresponding period of the prior fiscal year, an increase of $18.1 million.
Operating expenses were $66.8 million during the three months ended March 31, 2019 as compared to $52.1 million during the corresponding period of the prior fiscal year, an increase of $14.8 million.
Operating income was $13.7 million during the second quarter of fiscal year 2019 as compared to $10.3 million for the corresponding period of the prior fiscal year.
This compares to income from continuing operations of $62.5 million for the corresponding period of the prior fiscal year, which included the reversal of the valuation allowance reserve against U.S. deferred income tax assets of $58.0 million.
Results of Operations - Revenue for the six months ended March 31, 2019 increased to $377.8 million, or by 26%, as compared to the corresponding period of the prior fiscal year.
Gross margin was 40.4% for the six months ended March 31, 2019 as compared to 38.9% for the corresponding period of the prior fiscal year, an increase of $36.0 million.
Operating expenses were $133.6 million during the six months ended March 31, 2019 as compared to $101.4 million during the corresponding period of the prior fiscal year, an increase of $32.2 million.


item3.txt
Our primary interest rate risk exposure results from changes in the short-term LIBOR rate, the federal funds effective rate and the prime rate.


item4.txt



part2.txt



